Alterity Therapeutics Ltd Stock Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 107M 93.85M 86.44M 80.24M 152M 10.22B 154M 1.03B 403M 5.02B 402M 394M 17.4B | P/E 2026 * |
-0.42x | P/E 2027 * | -0.41x |
|---|---|---|---|---|---|
| Enterprise Value | 61.97M 54.28M 49.99M 46.4M 88.12M 5.91B 89.31M 598M 233M 2.9B 233M 228M 10.06B | EV / Sales 2026 * |
24.1x | EV / Sales 2027 * | 55.2x |
| Free-Float |
91.47% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 2021-01-06 |
Abby Niven
DFI | Director of Finance/CFO | - | 2024-09-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 2005-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 2011-08-07 |
David Stamler
BRD | Director/Board Member | 65 | 2025-11-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 101M | |
| +1.08% | +8.57% | +3.61% | +9.34% | 49.92B | |
| +0.40% | -1.37% | +401.69% | +625.15% | 40.23B | |
| -0.52% | +6.57% | +25.41% | -5.37% | 34.55B | |
| +3.97% | +6.71% | +26.06% | +63.36% | 33.09B | |
| -4.19% | +6.03% | +3.76% | +32.17% | 27.51B | |
| -2.40% | +1.60% | - | - | 17.05B | |
| +1.34% | +5.68% | +75.77% | +141.51% | 15.92B | |
| -0.95% | +0.76% | +12.92% | +21.59% | 13.86B | |
| +1.69% | +3.09% | +93.44% | +99.19% | 13.52B | |
| Average | +0.25% | +5.72% | +80.33% | +123.37% | 27.3B | |
| Weighted average by Cap. | +0.24% | +6.43% | +91.13% | +141.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.25M 2.07M 1.92M 3.65M 245M 3.7M 24.8M 9.65M 120M 9.65M 9.43M 417M | 1.2M 1.05M 968K 899K 1.71M 114M 1.73M 11.59M 4.51M 56.2M 4.51M 4.41M 195M |
| Net income | -14.62M -12.81M -11.8M -10.95M -20.79M -1.39B -21.07M -141M -54.95M -685M -54.92M -53.71M -2.37B | -29.6M -25.93M -23.88M -22.16M -42.09M -2.82B -42.66M -286M -111M -1.39B -111M -109M -4.81B |
| Net Debt | -45.19M -39.58M -36.45M -33.84M -64.25M -4.31B -65.12M -436M -170M -2.12B -170M -166M -7.34B | -40.88M -35.8M -32.98M -30.61M -58.13M -3.9B -58.91M -395M -154M -1.91B -154M -150M -6.64B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
